Drug Profile
Research programme: anti-G(M2) ganglioside monoclonal antibodies - GlaxoSmithKline
Alternative Names: Anti-ganglioside GM2 monoclonal antibodies - GlaxoSmithKlineLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator University of Massachusetts Medical School
- Developer GlaxoSmithKline
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Mar 2008 No development reported - Preclinical for Cancer in USA (Parenteral)
- 19 Nov 2003 Preclinical trials in Cancer in USA (Parenteral)